Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays

Sci Rep. 2021 Jul 21;11(1):14893. doi: 10.1038/s41598-021-94453-5.

Abstract

Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT. Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays. There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / analysis*
  • Antibodies, Viral / immunology
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • COVID-19 / virology
  • COVID-19 Testing / methods*
  • Child
  • Child, Preschool
  • Female
  • Germany / epidemiology
  • Humans
  • Immunoglobulin G / analysis
  • Immunoglobulin G / immunology
  • Male
  • Middle Aged
  • SARS-CoV-2 / immunology*
  • Sensitivity and Specificity
  • Seroepidemiologic Studies

Substances

  • Antibodies, Viral
  • Immunoglobulin G